CNTA vs. IMNM, MNKD, SRRK, MIRM, PRTA, XNCR, OCUL, COLL, BLTE, and MGNX
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Immunome (IMNM), MannKind (MNKD), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Xencor (XNCR), Ocular Therapeutix (OCUL), Collegium Pharmaceutical (COLL), Belite Bio (BLTE), and MacroGenics (MGNX). These companies are all part of the "medical" sector.
Immunome (NASDAQ:IMNM) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
In the previous week, Centessa Pharmaceuticals had 5 more articles in the media than Immunome. MarketBeat recorded 9 mentions for Centessa Pharmaceuticals and 4 mentions for Immunome. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Immunome's score of 0.25 indicating that Immunome is being referred to more favorably in the media.
44.6% of Immunome shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 20.0% of Immunome shares are owned by insiders. Comparatively, 11.5% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Immunome has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Centessa Pharmaceuticals' net margin of -761.92%. Immunome's return on equity of -56.72% beat Centessa Pharmaceuticals' return on equity.
Immunome received 2 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 66.67% of users gave Immunome an outperform vote while only 48.78% of users gave Centessa Pharmaceuticals an outperform vote.
Immunome presently has a consensus price target of $32.67, suggesting a potential upside of 128.92%. Centessa Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 5.71%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Immunome is more favorable than Centessa Pharmaceuticals.
Immunome has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Summary
Immunome beats Centessa Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
